AvenCell Therapeutics Secures $112M in Series B Funding to Advance Innovative Switchable CAR-T Cell Therapies

Watertown, MA, October 22, 2024 (PRNewswire) -- AvenCell Therapeutics has secured $112 million in Series B funding to enhance its switchable CAR-T cell therapy platform. The investment, led by Novo Holdings, will support clinical validation of therapies targeting hematologic malignancies and autoimmune diseases. With a distinguished board and a focus on innovative treatment options, AvenCell aims to transform patient care in the cell therapy space.

Read full article here.